Candel Therapeutics(NASDAQ) CADL

Candel Therapeutics uses modified viruses to help people fight cancer. These treatments teach the immune system to recognize and kill tumors. The company focuses on common diseases like prostate and lung cancer.

The Candel Treatment Menu

• Aglatimagene (CAN-2409): Engineered adenovirus treatment used with the drug valacyclovir for prostate, lung, and pancreatic cancers.
• Linoserpaturev (CAN-3110): Modified herpes virus therapy currently being tested for patients with recurring brain tumors.
• enLIGHTEN Discovery Platform: Technology system used to design new viral immunotherapies for various solid tumors.

Trials, Targets, and Timelines

• Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its lead candidate in May 2025.
• Paused clinical development of aglatimagene for pancreatic cancer in Oct. 2025 to prioritize other clinical programs.
• Secured a $100 million agreement with RTW Investments for milestone payments upon potential FDA approval in Feb. 2026.
• Opened enrollment for the AURORA pivotal phase 3 clinical trial in lung cancer in June 2026.

What Sets Candel Apart

Candel creates off-the-shelf treatments that are ready-made and do not need to be customized for each individual patient. These therapies can trigger an abscopal effect, where a local injection causes the immune system to attack cancer throughout the entire body.

A Look at the Numbers

• Net loss was $38.9 million for the three months ended June 30, 2026.
• Research and development expenses reached $19.8 million for the three months ended June 30, 2026.
• General and administrative expenses were $6.9 million for the three months ended June 30, 2026, up $2.7 million year over year.
• Cash and cash equivalents totaled $201.6 million as of June 30, 2026.
• Total debt was $47.8 million as of June 30, 2026.

Bottom Line

Candel has transitioned from its original form as Advantagene to a public biotechnology firm with advanced clinical trials. The company builds its pipeline through its proprietary discovery platform while moving toward potential regulatory approval for its lead candidate.